BioCentury
ARTICLE | Clinical News

Filgotinib meets in Phase III FINCH 2 study for RA

September 11, 2018 11:32 PM UTC

Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said both doses of filgotinib met the primary and all key secondary endpoints in the Phase III FINCH 2 trial to treat rheumatoid arthritis. Filgotinib is an oral Janus kinase-1 (JAK-1) inhibitor.

FINCH 2 enrolled 448 patients with moderately to severely active RA who were on a stable dose of conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and had prior inadequate response or intolerance to biologic agents. On the primary endpoint, a significantly greater proportion of patients who received once-daily 100 and 200 mg doses of filgotinib achieved a 20% improvement in ACR20 at week 12 vs. placebo (57.5% and 66%, respectively, vs. 31.1%, p<0.001 for both)...